Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Aditya Bardia, M.D.

Description

Summary

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.

Official Title

SERIES: SEquencing Sacituzumab Govitecan AfteR T-DXd In ER+/HER2 LOW MetaStatic Breast Cancer

Keywords

Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Low Breast Cancer, Breast Neoplasms, Sacituzumab govitecan, Sacituzumab Govitecan (SG) Infusion

Eligibility

Locations

  • UCLA Jonsson Comprehensive Cancer Center not yet accepting patients
    Los Angeles California 90404 United States
  • Winship Cancer Institute at Emory University not yet accepting patients
    Atlanta Georgia 30322 United States
  • Miami Cancer Institute at Baptist Health, Inc. accepting new patients
    Miami Florida 33176 United States

Lead Scientist at UCLA

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Reshma L. Mahtani, D.O.
ID
NCT06263543
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 75 study participants
Last Updated